Antibodies Remain 6 Months After Chikungunya Vaccine Administered in Youngest Children
Today, Valneva announced results from its phase 2 clinical trial, which demonstrated positive 6-month antibody persistence and safety for its single-shot chikungunya vaccine, VLA1553 (Ixchiq). 1 “The six months persistence and safety data in children are aligned with the robust antibody response and safety profile we reported in adolescents after a single vaccination,” Valneva Chief […]
First Participant Enrolled in Phase 2 Study for Investigational Antifungal For Cryptococcal Meningitis
Image credit: Mycovia Pharmaceuticals This week, Mycovia Pharmaceuticals announced it has enrolled its first participant for its phase 2 PLATFORM-CM clinical trial evaluating oteseconazole for cryptococcal meningitis.1 This is an open-label randomized trial with single or potentially multiple interventional arms to compare the efficacy and safety of antifungal investigational therapies, including oteseconazole, to the standard […]
Ceftolozane/Tazobactam Shows Strong Activity Against ESBL E coli, But Gaps Remain for K pneumoniae
A recent study presented by Taylor Hein, MLS, at the 2025 MAD-ID Meeting explored the in vitro activity of ceftolozane/tazobactam (C/T) against ESBL-producing Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis from clinical samples. Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae continue to pose serious challenges in clinical settings due to resistance to extended-spectrum cephalosporins. While carbapenems remain a […]
Vancomycin Loading Doses Improve Target Timing and Safety in 61,000+ Cases
A large real-world retrospective cohort study presented at MAD-ID 2025 by Tiffany Lee, PharmD, an infectious diseases pharmacist at InsightRX, evaluated the impact of vancomycin loading doses on pharmacokinetic target attainment and safety outcomes. This multi-center analysis spanned 61,155 patient encounters across 158 organizations, making it one of the largest investigations to date on vancomycin […]
No Significant Difference Between Doxycycline and Minocycline for Bone and Joint Infections
A multi-hospital retrospective cohort study conducted across Indiana University Health (IU Health) hospitals has found no significant differences in treatment outcomes between doxycycline and minocycline for managing bone and joint infections. The study, presented at MADID 2025, by William R. Mikesell, PharmD, PGY2 infectious diseases pharmacy resident at Indiana University Health, builds on the foundation […]
Immunocompromised Patients on OPAT Face Nearly Double the Risk of 30-Day Readmission
A retrospective study presented at MAD-ID 2025 suggests that immunocompromised (IC) patients receiving outpatient parenteral antimicrobial therapy (OPAT) are at significantly greater risk for unplanned 30-day hospital readmissions compared with non-immunocompromised (non-IC) patients, though rates of infection-related readmissions and central venous access device (CVAD) complications were not significantly different between groups. Christina Lee, PharmD, and […]
Gyre Therapeutics’ Hydronidone Meets Primary Endpoint in Phase 3 Hepatitis B Trial
Lungen Lu, MD Image Credit: Hepatology Digest on LinkedIn Hydronidone met the primary endpoint in a pivotal phase 3 trial evaluating its efficacy and safety for the treatment of liver fibrosis in patients with chronic hepatitis B (CHB) in China, according to a press release from Gyre Therapeutics.1 The trial met its primary endpoint for […]
Long-Acting, Off-Label Alternative for Serious Bacterial Infections
David Goodman-Meza, MD, PhD The long-acting lipoglycopeptides (laLGPs) dalbavancin and oritavancin, currently indicated for skin and skin structure infections, were as effective as daily standard-of care (SOC) antibiotics in step-down regimens for gram-positive endocarditis, bacteremia, osteomyelitis and septic arthritis, in an emulation trial of the off-label use.1 These agents may be of particular value for […]
VOWST Maintains Consistent Safety Profile in rCDI Patients with Comorbidities
At the 2025 MAD-ID meeting, Dianne Nguyen, MD, head of medical affairs for the pharmaceutical division at Nestlé Health Science, presented new data demonstrating the consistent safety profile of VOWST™ (fecal microbiota spores, live–brpk) in adults with recurrent Clostridioides difficile infection (rCDI), including those with significant comorbid conditions. The findings come from an integrated analysis […]
Reviewing the Efficacy and Safety of Omadacycline in Immunocompromised Patients
In a new study presented at MAD-ID, omadacycline was found to have an 86% clinical success rate across a wide-range of infections and pathogens in an immunocompromised population. “This is an effective antibiotic, particularly in this patient population,” study investigator Sean Van Helden, PharmD, Postdoctoral Infectious Diseases Pharmacotherapy fellow, Wayne State University, said. The most […]
